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Objectives Our purpose was to assess the diagnostic utility of mid-regional pro–atrial natriuretic peptide (MR-proANP) for
the diagnosis of acute heart failure (AHF) and the prognostic value of mid-regional pro-adrenomedullin (MR-
proADM) in patients with AHF.
Background There are some caveats and limitations to natriuretic peptide testing in the acute dyspneic patient.
Methods The BACH (Biomarkers in Acute Heart Failure) trial was a prospective, 15-center, international study of 1,641
patients presenting to the emergency department with dyspnea. A noninferiority test of MR-proANP versus
B-type natriuretic peptide (BNP) for diagnosis of AHF and a superiority test of MR-proADM versus BNP for 90-day
survival were conducted. Other end points were exploratory.
Results MR-proANP (120 pmol/l) proved noninferior to BNP (100 pg/ml) for the diagnosis of AHF (accuracy differ-
ence 0.9%). In tests of secondary diagnostic objectives, MR-proANP levels added to the utility of BNP levels in
patients with intermediate BNP values and with obesity but not in renal insufficiency, the elderly, or patients
with edema. Using cut-off values from receiver-operating characteristic analysis, the accuracy to predict 90-day
survival of heart failure patients was 73% (95% confidence interval: 70% to 77%) for MR-proADM and 62% (95%
confidence interval: 58% to 66%) for BNP (difference p  0.001). In adjusted multivariable Cox regression, MR-
proADM, but not BNP, carried independent prognostic value (p  0.001). Results were consistent using NT-
proBNP instead of BNP (p  0.001). None of the biomarkers was able to predict rehospitalization or visits to the
emergency department with clinical relevance.
Conclusions MR-proANP is as useful as BNP for AHF diagnosis in dyspneic patients and may provide additional clinical utility
when BNP is difficult to interpret. MR-proADM identifies patients with high 90-day mortality risk and adds prog-
nostic value to BNP. (Biomarkers in Acute Heart Failure [BACH]; NCT00537628) (J Am Coll Cardiol 2010;55:
2062–76) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.025Administration Medical Center, La Jolla, California; ¶Medical University, Faculty of
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May 11, 2010:2062–76 Mid-Region Pro-Hormone Markers in Acute Dyspnean patients presenting with shortness of breath, an accurate
nd rapid diagnosis is critical. Misdiagnoses result in de-
ayed or erroneous treatment that may lead to adverse
utcomes, including increased mortality, and greater costs
1,2). Making a late diagnosis of acute heart failure (AHF)
lso has significant adverse prognostic ramifications (3).
ecause natriuretic peptide (NP) testing with either B-type
atriuretic peptide (BNP) or N-terminal pro–B-type natri-
retic peptide (NT-proBNP) improves diagnostic accuracy,
heir use in the evaluation of dyspnea is recommended as a
tandard adjunct to history, physical examination, and other
aboratory tests (4). Unfortunately, NP testing is limited by
aveats that may make their interpretation challenging.
hese include intermediate “gray zone” values, and nuances
n interpreting levels in the settings of renal dysfunction,
besity, and advanced age.
See page 2077
Adrenomedullin (ADM), a vasodilatory peptide with
otent hypotensive effects, is expressed in many different
issues (5). Its plasma levels are elevated in patients with
hronic heart failure (6) and increase with disease severity
7,8). However, its clinical application has been impeded
ue to biologic instability of plasma measurements.
Recently, several novel immunoassays for analytes relevant
o cardiovascular regulation have been developed for the
etection of the stable prohormone fragment as a “mirror” of
ature hormone release (9–12). New immunoassays can be
irected at stable mid-region prohormones that are stoicho-
etrically related to synthesis of the biologically active unstable
ragment. Thus, the measurement of mid-region pro-atrial
atriuretic peptide (MR-proANP) and mid-region pro-
drenomedullin (MR-proADM) can be performed and may
rovide clinically relevant diagnostic and outcome information
n addition to standard NP testing.
ethods
he BACH (Biomarkers in Acute Heart Failure) trial was
prospective, 15-center international study of 1,641 pa-
ients presenting to the emergency department (ED) with
yspnea. There were 2 primary end points. The primary
iagnostic end point was the diagnosis of AHF, where the
oninferiority of MR-proANP compared with BNP was
valuated. The primary prognostic end point tested was
0-day survival, where the superiority of the utility of
ealand; §§Athens University Hospital Attikon, Athens, Greece;  Sant’Andrea
ospital, University La Sapienza, Rome, Italy; ¶¶VA Minneapolis, Minnesota;
#University of Leicester, Leicester, United Kingdom; ***University of California,
an Diego, California; †††University of Maryland, Baltimore, Maryland; ‡‡‡Uni-
ersity of California, San Diego School of Medicine, San Diego, California;
§§BRAHMS Aktiengesellschaft Biotechnology Centre Hennigsdorf, Berlin, Ger-
any; and the   Centre for Clinical and Basic Research IRCCS San Raffaele, Rome,
taly. For full author disclosures, please see the end of this article.f
Manuscript received August 18, 2009; revised manuscript received February 4,
010, accepted February 4, 2010.R-proADM versus BNP for
redicting survival over a period
f 90 days was evaluated in pa-
ients with a diagnosis of AHF.
utcomes investigated were all-
ause and cardiovascular death,
ll-cause and cardiovascular re-
ospitalization, and all-cause and
ardiovascular revisit.
tudy population. This study
as approved by the institutional
eview boards of all 15 participat-
ng centers, and included 8 U.S.
enters (831 patients enrolled);
European centers in Germany,
witzerland, Italy, Greece, United
ingdom, and Poland (726 pa-
ients enrolled); and 1 New Zea-
and hospital (84 patients en-
olled). A total of 1,641 patients
ere enrolled from March 2007 to
ebruary 2008. To be eligible, pa-
ients had to report shortness of
reath as their primary complaint
pon presentation to the ED. Pa-
ients were excluded if they were
18 years of age, unable to pro-
ide consent, had an acute ST-segment elevation myocardial
nfarction, were receiving hemodialysis, or had renal failure.
For each patient enrolled in the study, ED physicians,
linded to the investigational marker results, assessed the
robability that the patient had AHF or pneumonia by 2
eparate visual analog scales, assigning a value of 0% to
00% clinical diagnostic certainty.
onfirmation of diagnosis. To determine the gold stan-
ard diagnosis, 2 cardiologists independently reviewed all
edical records pertaining to the patient and independently
lassified the diagnosis as dyspnea due to heart failure or due
o another cause. Both cardiologists were blinded to the
ther’s assessments, investigational markers, and the ED
hysician’s diagnosis. They had access to the ED case report
orms, which included medical history plus data on chest
adiography, radionuclide angiography, echocardiography,
nd cardiac catheterization as available, as well as the
ospital course for patients who were admitted. In the event
f diagnostic disagreement between the cardiology review-
rs, they were asked to meet to come to a common
onclusion. If they were unable to come to a common
onclusion, a third cardiology adjudicator was assigned by
he end points committee to determine a final diagnosis. In
ases of pneumonia, its diagnosis was defined by the criteria
odified from Leroy et al. (13) and Fine et al. (14).
easurement of biomarkers. All blood samples were
ollected in plastic tubes containing ethylenediaminetetra-
cetic acid, and plasma was stored at 70°C in plastic
Abbreviations
and Acronyms
AHF  acute heart failure
AUC  area under the
curve
BNP  B-type natriuretic
peptide
CI  confidence interval
CV  coefficient of
variation
ED  emergency
department
HR  hazard ratio
IQR  interquartile range
MR-proADM  mid-regional
pro-adrenomedullin
MR-proANP  mid-regional
pro-atrial natriuretic
peptide
NP  natriuretic peptide
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
ROC  receiver-operating
characteristicreezer vials. MR-proANP and MR-proADM were mea-
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mmunoassay on the KRYPTOR System (BRAHMS AG,
ennigsdorf/Berlin, Germany) in the core laboratory at the
niversity of Maryland School of Medicine. Both auto-
ated assays are based on the sandwich chemiluminescence
ssays, which are described in detail elsewhere (5,6) and
hich have been used in other studies (15–19).
Performance of MR-proANP in this laboratory included
limit of quantitation of 4.5 pmol/l, within-run imprecision
Patient Characteristics by DiagnosisTable 1 Patient Characteristics by Diagnosi
Variables n
Demographics
Age, yrs 1,641
Male 1,641
Race 1,626
White
Black
Other
Recent history
Smoking 1,593
Wheezing 1,543
Weight gain 1,438
Night sweats 1,495
Orthopnea 1,536
Dyspnea at rest 1,605
Examination variables
Heart rate, beats/min 1,632
Systolic BP, mm Hg 1,631
Diastolic BP, mm Hg 1,630
BMI, kg/m2 1,399
Rales 1,624
S3 1,580
Murmur 1,604
Elevated JVP 1,539
Edema 1,615
Ascites 1,579
Wheezing 1,619
History variables
Arrhythmia 1,555
Asthma 1,594
CRI 1,584
HF 1,597
CAD 1,587
COPD 1,594
DM 1,621
Hyperlipidemia 1,549
Hypertension 1,614
MI 1,584
Pulmonary embolism 1,604
CABG 1,615
Angioplasty/stent 1,602
Stroke/CVA 1,608
Pacemaker/ICD 1,616
Prosthetic valve 1,612oefficient of variation (CV) of 1.2% and total imprecision lCV) of 5.4%. For MR-proADM, the limit of quantifica-
ion was 0.23 nmol/l; the within-run imprecision (CV) was
.9%, and the between-run (CV) was 9.8%. The BNP was
easured with Triage 2-site immunoassay reagents (Biosite,
an Diego, California) formatted for Beckman-Coulter
nstrumentation (Brea, California). Performance in the
aboratory included a limit of quantitation of 5.0 ng/l,
ithin-run imprecision (CV) of 1.5% and total imprecision
CV) of 3.0%. NT-proBNP was measured by electrochemi-
Non-AHF
 1,073)
AHF
(n  568) p Value
9.8 17.0 71.2 13.8 0.001
04 (47.0) 355 (62.5) 0.001
0.001
59 (62.1) 431 (76.3)
56 (33.6) 120 (21.2)
46 (4.3) 14 (2.5)
44 (33.0) 125 (22.7) 0.001
59 (35.4) 109 (20.6) 0.001
12 (11.8) 137 (28.0) 0.001
30 (23.4) 94 (18.3) 0.025
49 (35.0) 340 (63.0) 0.001
18 (49.3) 277 (49.9) 0.834
2.6 21.6 89.2 24.8 0.005
9.7 26.8 143.0 31.8 0.027
9.6 16.4 83.0 18.7 0.001
9.6 9.1 28.5 8.1 0.035
16 (20.3) 308 (54.8) 0.001
6 (0.6) 38 (7.0) 0.001
98 (9.3) 156 (28.3) 0.001
71 (7.0) 200 (38.2) 0.001
44 (23.1) 344 (61.5) 0.001
15 (1.5) 26 (4.8) 0.001
50 (33.0) 102 (18.2) 0.001
68 (16.6) 237 (43.6) 0.001
88 (27.7) 30 (5.4) 0.001
75 (7.2) 171 (31.3) 0.001
03 (19.6) 366 (65.2) 0.001
32 (22.3) 271 (49.5) 0.001
41 (32.7) 130 (23.6) 0.001
44 (23.1) 218 (38.6) 0.001
30 (32.4) 240 (45.3) 0.001
42 (60.9) 438 (78.2) 0.001
28 (12.3) 172 (31.5) 0.001
49 (4.7) 36 (6.5) 0.127
66 (6.2) 92 (16.5) 0.001
96 (9.1) 108 (19.6) 0.001
89 (8.5) 76 (13.7) 0.001
55 (5.2) 107 (19.1) 0.001
13 (1.2) 30 (5.4) 0.001
Continued on next pages
(n
5
5
6
3
3
3
1
2
3
5
9
13
7
2
2
2
3
1
2
2
2
3
2
3
6
1uminescence on the ElecSys 2010 analyzer (Roche Diag-
n
t
i
3
b
S
s
(
t
a
(
a
s
s
s
l
a
s
C
b
r
c
r
P
n
e
t
t
p
M
p
r
p
P
n
s
f
r
m
A
e
c
B
o
a
f
c
C
c
2
p
m
a
q
M
r
M
B
a
H
rovasc
MI  m
2065JACC Vol. 55, No. 19, 2010 Maisel et al.
May 11, 2010:2062–76 Mid-Region Pro-Hormone Markers in Acute Dyspneaostics, Indianapolis, Indiana). Performance in the labora-
ory included a limit of quantitation of 10.0 ng/l, within-run
mprecision (CV) of 1.5%, and total imprecision (CV) of
.0%. All blood samples were processed by personnel
linded from any patient data.
tatistical analysis. Values are expressed as means and
tandard deviations, medians and interquartile ranges
IQRs), or counts and percentages as appropriate. Diagnos-
ic groups were compared with independent-samples t tests
nd chi-square tests as appropriate. Four primary objectives
MR-proANP as noninferior to BNP and MR-proANP as
dditive to BNP for diagnosis, and MR-proADM as
uperior to BNP and MR-proADM as additive to BNP for
urvival) were evaluated using a p value of 0.0125 as the
ignificance criterion for each to protect the global error
evel in this trial evaluating multiple biomarkers. All other
nalyses are exploratory and utilized a p value of 0.05 for
ignificance. The secondary analyses utilized logistic and
ox regressions, McNemar tests, and survival curves plotted
y the Kaplan-Meier method. Additional methods included
eceiver-operating characteristic (ROC) curves and the
omparison of correlated ROC curves (20) and Spearman
ank-order correlation.
rimary MR-proANP diagnostic utility. The first diag-
ostic question was whether MR-proANP could be consid-
red noninferior to BNP for diagnosis of AHF. McNemar’s
est with exact computation was employed as the hypothesis
est with a noninferiority margin of 10%. Cut points were
re-specified as 100 pg/ml for BNP and 120 pmol/l for
R-proANP. Using these same cut points, the second
ContinuedTable 1 Continued
Variables n
Outpatient medications (known)
Aspirin 1,616
Clopidogrel 1,617
Warfarin 1,615
Beta-blockers 1,613
ACE inhibitors or ARB 1,616
CCB 1,614
Statins 1,617
Diuretics 1,618
Digoxin 1,617
Aldosterone inhibitor 1,615
Antiarrhythmics 1,616
Nebulizer/inhaler 1,613
Steroids 1,582
Antibiotics 1,614
Smoking cessation therapy 1,577
Other 1,593
Values are mean  SD or n (%) and compared with independent sam
ACE  angiotensin-converting enzyme; AHF  acute heart failure;
pressure; CABG coronary artery bypass graft surgery; CAD coronar
pulmonary disease; CRI  chronic renal insufficiency; CVA  cereb
implantable cardioverter-defibrillator; JVP  jugular venous pressure;rimary diagnostic objective was evaluated in a logistic iegression model using elevated BNP and elevated MR-
roANP as predictors.
rimary MR-proADM prognostic utility. The first prog-
ostic objective was to test whether MR-proADM was
uperior to BNP for prognosis in patients admitted for heart
ailure. Three different outcomes were considered: death,
ehospitalization, and revisit to the ED, with all-cause
ortality at 90 days considered as the primary end point.
nalysis was conducted for all-cause events, as well as for
vents classified as cardiovascular only. The first step was to
onduct ROC analysis separately for MR-proADM and
NP to identify the cut points that maximized the product
f sensitivity times specificity. Subjects were categorized as
bove or below these cut points for both MR-proADM and
or BNP. Categories were then compared to outcomes and
lassified as correct or incorrect in predicting the end point.
orrectness of prediction from the BNP cut point was
ompared with that of the MR-proADM cut point using a
-sided McNemar’s test. Log-transformed values of MR-
roADM and BNP were also evaluated in a Cox regression
odel to evaluate the contribution of MR-proADM over
nd above that of BNP as the second primary prognostic
uestion.
Finally, to test for differences in the predictive value of
R-proADM and NT-proBNP, we used the likelihood
atio chi-square test for nested models to assess whether
R-proADM adds predictive value to a clinical model with
NP or NT-proBNP and vice versa. For continuous vari-
bles, hazard ratios (HRs) were standardized to describe the
R for a biomarker change of 1 IQR; and 95% confidence
Non-AHF
 1,073)
AHF
(n  568) p Value
22 (30.0) 252 (44.4) 0.001
65 (6.1) 66 (11.6) 0.001
94 (8.8) 163 (28.7) 0.001
92 (27.2) 335 (59.0) 0.001
59 (33.5) 321 (56.5) 0.001
21 (20.6) 148 (26.1) 0.047
84 (26.5) 233 (41.0) 0.001
73 (34.8) 401 (70.6) 0.001
32 (3.0) 88 (15.5) 0.001
48 (4.5) 101 (17.8) 0.001
33 (3.1) 59 (10.4) 0.001
49 (41.8) 112 (19.7) 0.001
14 (29.3) 77 (13.6) 0.001
61 (15.0) 42 (7.4) 0.001
24 (2.2) 4 (0.7) 0.049
68 (62.3) 362 (63.7) 0.785
est or Fisher exact test, respectively.
angiotensin-receptor blocker; BMI  body mass index; BP  blood
disease; CCB calcium-channel blocker; COPD chronic obstructive
ular accident; DM  diabetes mellitus; HF  heart failure; ICD 
yocardial infarction.(n
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ach model was assessed by the model likelihood ratio
hi-square statistic. Survival curves plotted by the Kaplan-
eier method were used for illustrative purposes. The
ultivariate logistic regression models, adjusted Cox regres-
ion models, time-dependent area under the curve (AUC)
nalysis, as well as Kaplan-Meier plots using quartiles were
dded to provide a more in-depth picture of predictive
erformance of the biomarkers under evaluation. They were
ot part of the statistical analysis plan and are considered to
e exploratory.
All statistical analyses were performed using R version
.5.1 (The R Project for Statistical Computing, Wien,
ustria), SAS version 9.1 (SAS Institute, Cary, North
arolina), and Statistical Package for the Social Sciences
ersion 16.0 (SPSS Inc., Chicago, Illinois).
The data management center and research department of
he VA San Diego Healthcare System, San Diego, Califor-
ia, were responsible for data quality control and statistical
nalysis. The academic principal investigators of the trial
old an independent copy of the trial database and were able
o perform independent statistical analysis.
esults
total of 1,641 patients were evaluated. Of these, the
djudicated diagnosis was AHF in 568 patients (34.6%). In
etermining the presence or absence of AHF, the 2 adju-
icating cardiologists agreed in all but 25 (1.5%) of 1,641
ases (kappa 0.966, p 0.001). In these instances, a third
ardiologist made the final determination. The patient
haracteristics among the AHF and non-AHF groups are
resented in Table 1. The AHF cases were older, more
ikely to be male, and evidenced classic signs and symptoms
f heart failure more frequently than non-AHF patients.
Valid measurements for MR-proANP and MR-
roADM were obtained for 99.6% of all patient samples (6
ailures of 1,641). For BNP and NT-proBNP, the rate was
9.8% (3 failures) and 98.9% (18 failures), respectively. The
R-proANP ranged from 3.9 to 2510.0 pmol/l, with a
edian of 174.5 pmol/l and IQR from 66.5 to 369.4 pmol/l.
he MR-proADM ranged from 0.1 to 12.6 nmol/l, with a
edian of 0.88 nmol/l and IQR from 0.57 to 1.44 nmol/l.
he BNP ranged from 0.5 to 10,746 pg/ml, with a median
f 164 pg/ml and IQR from 36 to 574 pg/ml. The
T-proBNP ranged from 3 to 120,083 pg/ml, with a
edian of 833 pg/ml and IQR from 112 to 4115 pg/ml.
cute Heart Failure Diagnostic Performance of MR-proANP Cut at 1Table 2 Acute Heart Failure Diagnostic Performance of MR-pro
Measure Sensitivity (95% CI) Specificit
BNP 100 pg/ml 95.6% (93.6–97.0) 61.9% (5
MR-proANP 120 pmol/l 97.0% (95.2–98.2) 59.9% (5
Difference 1.4% 2
Upper 95% limit 0.2% 3
Noninferiority p value 0.001 0NP  B-type natriuretic peptide; CI  confidence interval; MR-proANP  mid-regional pro-atrial natriurepearman correlation between MR-proANP and both BNP
nd NT-proBNP was 0.92, and between BNP and NT-
roBNP, it was 0.96. Spearman correlations between MR-
roADM and MR-proANP, BNP, and NT-proBNP were
.78, 0.72, and 0.76, respectively.
Of the 1,641 patients, 568 (34.6%) were diagnosed with
HF, 201 (12.2%) with chronic obstructive pulmonary
isease, 130 (7.0%) with asthma, 112 (6.8%) with pneumo-
ia, 106 (6.5%) with chest pain, 61 (3.7%) with bronchitis,
5 (3.4%) with arrhythmia, 39 (2.4%) with acute coronary
yndrome, 38 (2.3%) with pulmonary embolism, 27 (1.6%)
ith influenza, and 304 (18.5%) with other diseases.
iagnosis of AHF. The primary diagnostic objective of
he BACH study was to demonstrate that the MR-proANP
ut point of 120 pmol/l would be noninferior to a BNP cut
oint of 100 pg/ml for the diagnosis of AHF. This level of
R-proANP was defined prospectively and confirmed in
ilot data. Table 2 shows the sensitivity, specificity, and
verall accuracy (% correct) for both measurements. The
bsolute difference in accuracy was 0.9%. The upper 95%
onfidence limit for the difference was 2.1%. That was less
han the noninferiority margin of 10% (p  0.001), sup-
orting the primary diagnostic objective of the study.
ifferences for sensitivity and specificity were also within
he noninferiority margin. These cut points yielded greater
ensitivity than specificity for both markers in this patient
ample.
Another diagnostic objective was to determine whether
levated MR-proANP could add to the diagnostic utility of
levated BNP. Using the same cut points as above, MR-
roANP added significantly to the diagnostic performance
f BNP in logistic regression (chi-square increase 89.3,
f  1, p  0.001). This corresponds to an increase in the
-statistic or AUC from 0.787 to 0.816 (p  0.001).
equiring both variables to be elevated for the diagnosis of
HF increases the overall accuracy from 73.6% for BNP
lone to 76.6% for the combined diagnosis. Both variables
ontributed to the identification of AHF (BNP odds ratio
OR]: 7.6, 95% CI: 4.6 to 2.4, p  0.001; and MR-
roANP OR: 11.5, 95% CI: 6.5 to 20.6, p  0.001).
The diagnostic performance was also evaluated by
OC analysis. The curves for MR-proANP, BNP, and
T-proBNP appear in Figure 1A. The AUC was com-
ared between correlated ROC curves. The area for BNP
xceeded that of MR-proANP by 0.01 (p  0.003)
hereas the AUCs for MR-proANP and NT-proBNP
mol/l and BNP Cut at 100 pg/mlCut at 120 pmol/l and BNP Cut at 100 pg/ml
CI) Accuracy (95% CI) NPV PPV
4.8) 73.6% (71.4–75.6) 96.4% 57.0%
2.8) 72.7% (70.5–74.8) 97.4% 56.0%
0.9% 1.0% 1.0%
2.1%
0.00120 pANP
y (95%
9.0–6
6.4–6
.1%
.8%
.001tic peptide; NPV  negative predictive value; PPV  positive predictive value.
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May 11, 2010:2062–76 Mid-Region Pro-Hormone Markers in Acute Dyspneaid not significantly differ (p  0.110). The strong
ssociation between BNP and MR-proANP is illustrated
n Figure 1B. Overall, 57.9% of the cases had BNP levels
100 pg/ml. The equal-percentile cut point for MR-
roANP was 130.3 pmol/l. Likewise, 28% of cases had
NP 500 pg/ml and 28% had MR-proANP 338
mol/l.
Local clinical laboratory values of BNP (n  865) or
T-proBNP (n  157) were available to ED physicians
nd adjudicating cardiologists in 60% (n  983) of all
atients. The ROC analysis omitting these 893 patients was
erformed for the remaining 658 patients, of whom 97
14.7%) had gold standard AHF diagnoses. In this subset of
atients, the AUC was 0.90 for both BNP and MR-
roANP, and MR-proANP was better than NT-proBNP
0.890, p  0.009).
The distributions of BNP and MR-proANP across var-
ous diagnostic groupings are shown in Figure 2. The
atterns and ranges follow closely across groups, with AHF
ighest and asthma lowest for both markers.
In patients with intermediate BNP or NT-proBNP
evels, renal insufficiency (creatinine 1.6 mg/dl), obesity
body mass index 30 kg/m2), advanced age (age 70
ears), or with edema present, log-transformed MR-
roANP added to a logistic regression model with log-
ransformed BNP or NT-proBNP to predict adjudicated
HF diagnosis demonstrated incremental value in the case of
ntermediate (100 to 500 pg/ml) BNP levels (chi-square 
0.53, p  0.001) and obesity (chi-square  6.85,
 0.009). Results were not significant for renal insuffi-
iency, the elderly, or with edema (chi-square  2.23, 3.14,
nd 0.77, respectively; p  0.135, 0.076, and 0.379, respec-
Figure 1 Comparison of Diagnostic Biomarkers
(A) Receiver-operating characteristic curves for B-type natriuretic peptide (BNP)
mid-regional pro-atrial natriuretic peptide (MR-proANP) (blue line) for detecting
AUC  area under the curve; CI  confidence interval.(green line), N-terminal pro–B-type natriuretic peptide (NT-proBNP) (red line), and
acute heart failure. (B) Spearman’s correlation between BNP and MR-proANP.ively). The incremental value of log-transformed MR-Figure 2 Box Plots of BNP and MR-proANP
Box plots of BNP (blue boxes) and MR-proANP (red boxes) in various diagnos-
tic groups. Boxes represent medians and interquartile ranges, whiskers repre-
sent 10th and 90th percentiles. ACS  acute coronary syndrome; AHF  acute
heart failure; COPD  chronic obstructive pulmonary disease; other abbrevia-
tions as in Figure 1.
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Mid-Region Pro-Hormone Markers in Acute Dyspnea May 11, 2010:2062–76roANP was significantly superior in all categories versus
T-proBNP levels (Table 3).
To further illustrate the properties of MR-proANP
ompared with BNP, Spearman correlation coefficients for
oth NPs were computed for each variable listed in Table 1.
hen, to compare the MR-proANP correlations with the
NP correlations, these were plotted as x-y pairs in Figure 3.
he Spearman correlation between sets of correlations for
he 2 markers was r  0.997, illustrating the significant
verlap between these variables.
The diagnostic utility of BNP and MR-proANP in a
ultivariable context is summarized in Table 4. Selected
emographic, history, and examination variables were in-
luded in logistic regression models with log-transformed
Figure 3 Spearman Correlations
Spearman correlations of each variable in Table 1 with BNP as related to the
correlation of that variable with MR-proANP. Each dot represents a different
clinical variable. The proximity of the dot to the diagonal shows the similarity of
the BNP and MR-proANP relationships to that clinical variable. Abbreviations as
in Figure 1.
dditive Value of MR-proANP in “Gray Zone” Areas for Logistic RegTable 3 Additive Value of MR-proANP in “Gray Zone” Areas for
Subgroup Measure Subgroup Criterion
BNP 100 pg/ml and 500 pg/ml
NT-proBNP 300 pg/ml and 900 pg/ml
NT-proBNP 300 pg/ml and 450 pg/ml, if age 50 yrs
300 pg/ml and 900 pg/ml, if age 50–75 yrs
300 pg/ml and 1,800 pg/ml, if age 75 yrs
Renal Creatinine 1.6 mol/l
Obese BMI 30 kg/m2
Elderly Age 70 yrs
Edema Present
T-proBNP  N-terminal pro–B-type natriuretic peptide; OR  odds ratio; other abbreviations as icNP or MR-proANP to illustrate their utility in models
ith clinical covariates. Both biomarkers show significance,
ut the ORs per log cannot be directly compared, since the
anges of BNP and MR-proANP are not the same. Stan-
ardizing these predictors yields an OR per standard devi-
tion unit of 7.66 (95% CI: 5.71 to 10.28) for BNP and 6.24
95% CI: 4.66 to 8.35) for MR-proANP.
Classifying the physician’s initial assessment of the
robability that the patient had AHF by a visual analog
cale into high (80%, n  227), low (20%, n  822),
nd indecisive (20% but 80%, n  556), the addition
f MR-proANP was capable of reducing the subgroup of
ndecisive by 29%.
rognosis of MR-proADM in patients with AHF. There
ere 130 deaths within 90 days (survival rate 92.1%, 95%
I: 90.7% to 93.3%). Survivors had a median MR-
roADM of 0.84 nmol/l (IQR 0.55 to 1.35 nmol/l) and
onsurvivors, 1.57 nmol/l (IQR 1.02 to 3.21 nmol/l, p 
.0001). In the subgroup of 568 patients diagnosed with
HF, there were 65 deaths within 90 days (90-day survival
ate 88.6%, 95% CI: 85.6% to 90.9%). Survivors had a
edian MR-proADM of 1.34 nmol/l (IQR 0.96 to 3.76
mol/l) and nonsurvivors, 2.07 nmol/l (IQR 1.19 to 3.64
mol/l, p  0.0001).
rognostic end points of death, rehospitalization, and
evisit. We evaluated the biomarkers MR-proADM, BNP,
nd NT-proBNP for their ability to predict both all-cause
r cardiovascular death, all-cause or cardiovascular rehospi-
alization, all-cause or cardiovascular revisit or any of the
entioned events, and all-cause or cardiovascular death in
atients diagnosed with AHF, with all-cause mortality at 90
ays considered the primary end point. Result are summa-
ized in terms of AUC values in Table 5 for 7, 30, and 90
ays after initial presentation at the ED. Prediction of
0-day all-cause and cardiovascular death, rehospitalization,
nd revisit is illustrated in Figure 4. Prediction was strongest
or cardiovascular death for all markers and at all time
oints, followed by death for any cause. For all other end
oints, prediction is either nonsignificant or significant but
ion Models to Predict Acute Heart Failurestic Regression Models to Predict Acute Heart Failure
MR-proANP Adds to BNP
MR-proANP Adds to
NT-proBNP
OR per Log10 p Value OR per Log10 p Value
0 5.7 0.001
8 16.1 0.004
8 9.5 0.008
3 2.5 0.135 9.5 0.001
8 6.8 0.009 17.4 0.001
8 2.6 0.076 6.7 0.001
8 1.7 0.379 7.4 0.001
s 1 and 2.ressLogi
n
49
22
28
56
51
65
58linically not relevant (AUC 0.65), except for short-term
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May 11, 2010:2062–76 Mid-Region Pro-Hormone Markers in Acute Dyspnearediction of revisits. The latter is, however, based on very
ew events, and must be interpreted carefully.
For prediction of rehospitalization and revisit, BNP
erforms best, and substantially better than NT-proBNP.
his advantage of BNP is lost for cardiovascular events if
he ROC analysis is limited to patients whose BNP was not
easured by the hospital at the initial ED presentation (n
66) (Fig. 5), suggesting that BNP knowledge influenced
he classification of cardiovascular events.
ll-cause mortality. All-cause mortality was the best pre-
ictable end point for all biomarkers. Cut points for
R-proADM, BNP, and NT-proBNP were determined
rom ROC analysis for 90-day survival. The optimal cut
oints were 1.985 nmol/l (n  153, or 27% higher) for
R-proADM, 1,021 pg/ml (n  218, or 38% higher)
or BNP, and 6,310 pg/ml (n  228, or 40% higher) for
T-proBNP. Using these cut points, accuracy was 74%
70% to 77%) for MR-proADM, 62% (58% to 66%) for
NP, and 64% (60% to 68%) for NT-proBNP (p  0.001
ompared with MR-proADM for both). The specificity was
6% (95% CI: 72% to 80%) for MR-proADM, and 63%
59% to 67%) for both BNP and NT-proBNP (p  0.001
or each vs. MR-proADM). The sensitivity was 53% (95%
I: 41% to 65%) for MR-proADM and BNP (not signif-
cantly different), and 69% (95% CI: 57% to 79%) for
T-proBNP (p 0.094 compared with MR-proADM and
NP).
Using logistic regression models to derive the probability
f death from the logs of both BNP and MR-proADM
ersus BNP alone, net reclassification improvement was
alculated following Pencina et al. (21) for probability
roups 6%, between 6% and 20%, and 20%. The
esulting net reclassification improvement was 38.8%. As
ultivariable Diagnosis Models With BNP and MR-proANPTable 4 Multivariable Diagnosis Models With BNP and MR-proA
Variables
Model With BNP
OR 95% CI
Log10 BNP, pg/ml 15.40 10.37–22.86
Log10 MR-proANP, pmol/l
Age, yrs 1.01 1.00–1.03
Male 1.57 1.10–2.24
History of
AHF 2.45 1.70–3.53
MI 1.00 0.66–1.53
COPD 0.42 0.28–0.63
DM 1.80 1.23–2.64
Examination
Rales 2.26 1.57–3.25
Wheezing 1.03 0.67–1.59
S3 2.54 0.76–8.52
Murmur 1.57 0.99–2.49
Edema 1.59 1.11–2.28
JVP 2.47 1.57–3.89
bbreviations as in Tables 1 to 3.encina et al. (21) note, the net reclassification improve- Lent is influenced by the probability cut points selected.
herefore, the integrated discrimination improvement was
lso calculated, and an integrated discrimination improve-
ent of 5.24% was achieved.
ox and ROC analyses. In univariate Cox proportional
azard analyses, all 3 biomarkers were prognostic of survival
t 90 days (Table 6). The HRs per log10 unit increase were
4.4 (95% CI: 5.8 to 35.7, p  0.001) for MR-proADM
nd 2.2 (95% CI: 1.2 to 3.8, p  0.008) for BNP. The HRs
tandardized for an increase by 1 IQR were 2.4 (95% CI: 1.8
o 3.3) for MR-proADM and 1.5 (95% CI: 1.1 to 2.1) for
NP. In multivariable models including both markers, as
ell as age, sex, and creatinine, only MR-proADM carried
ndependent prognostic utility from BNP and NT-proBNP
Table 6). MR-proADM added to a model using BNP
additional chi-square  23.90, df  1, p  0.001);
owever, BNP did not add to a model using MR-proADM
additional chi-square  0.01, df  1, p  0.906). Similar
esults were obtained when NT-proBNP was used instead
f BNP (data not shown).
Local laboratory troponin values were available in 511
90%) of 568 heart failure patients. In 107 (20.9%)
atients, they were elevated as per clinical laboratory
rotocols. In Cox regression models using MR-
roADM, BNP, NTproBNP, and troponin status (ele-
ated vs. not elevated with respect to the manufacturer’s
uidelines of the applied troponin assay), MR-proADM
emained an independent prognostic marker. As Table 6
emonstrates, troponin and MR-proADM both provided
ndependent prognostic utility, but BNP and NT-
roBNP did not. Among patients with AHF, MR-
roADM was an independent predictor of survival after
djusting for left ventricular (LV) ejection fraction (%),
Model With MR-proANP
p Value OR 95% CI p Value
0.001
47.85 25.82–88.66 0.001
0.078 1.00 0.99–1.01 0.968
0.013 1.58 1.12–2.22 0.009
0.001 2.41 1.69–3.44 0.001
0.991 1.14 0.76–1.72 0.518
0.001 0.44 0.30–0.65 0.001
0.003 1.77 1.22–2.55 0.002
0.001 2.28 1.61–3.24 0.001
0.890 0.97 0.64–1.48 0.901
0.130 2.73 0.77–9.67 0.120
0.053 1.42 0.91–2.21 0.119
0.012 1.67 1.18–2.35 0.004
0.001 2.89 1.87–4.46 0.001NPV end-diastolic dimension (cm), normal LV function,
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Mid-Region Pro-Hormone Markers in Acute Dyspnea May 11, 2010:2062–76nd presence of either systolic or diastolic dysfunction as
etermined by echocardiography (standardized HR: 2.3,
5% CI: 1.5 to 3.6, p  0.001; 318 [56%] AHF patients
ith echocardiography done, 295 [52%] AHF patients
ith valid ejection fraction). MR-proADM was further
valuated in combination with each available baseline
ovariate. In all bivariable models, MR-proADM re-
ained the strongest predictor (data not shown).
Figure 6 shows the comparison of areas under the ROC
urve for 90-day survival using the 3 peptides. The AUCs
or 90-day outcome for MR-proADM, BNP, and NT-
roBNP are 0.674, 0.606, and 0.664, respectively. For
0-day outcome, used as an exploratory end point, the
rognostic performance for MR-proADM increases to
.739, whereas those for BNP and NT-proBNP decrease to
.555 and 0.641, respectively. Compared with BNP and
TproBNP, MR-proADM demonstrated a unique prog-
ostic profile in the first 30 days after hospitalization.
urvival by quartiles of MR-proADM, BNP, and NT-
roBNP in AHF patients is illustrated in Kaplan-Meier
Summary of Predictive Performance for BNP, NTPredicting All-Cause or Cardiov s ular Death, Rof the Previous Events at 90, 30, and 7 D ys A
Table 5
Summary of Predictive Performance
Predicting All-Cause or Cardiovascu
of the Previous Events at 90, 30, a
End Point Follow-Up, Days Event
Mortality
All-cause 90 6
All-cause 30 3
All-cause 7 1
Cardiovascular 90 4
Cardiovascular 30 2
Cardiovascular 7 1
Rehospitalization
All-cause 90 20
All-cause 30 10
All-cause 7 2
Cardiovascular 90 12
Cardiovascular 30 7
Cardiovascular 7 1
ED visit
All-cause 90 14
All-cause 30 7
All-cause 7 1
Cardiovascular 90 8
Cardiovascular 30 5
Cardiovascular 7 1
Any event
All-cause 90 29
All-cause 30 15
All-cause 7 4
Cardiovascular 90 18
Cardiovascular 30 10
Cardiovascular 7 3
Area under the curve (AUC) values above 0.65 are marked in bold.
ED  emergency department; MR-proADM  mid-regional pro-adreurves shown in Figure 7. For MR-proADM, the cutoffs are n.97, 1.40, and 2.07 nmol/l for the 25th, 50th, and 75th
ercentiles, respectively. For BNP, cutoffs are 391, 740, and
,399 pg/ml, respectively; and for NT-proBNP, cutoffs are
,248, 5,017, and 10,455 pg/ml, respectively. Comparing
HF patients in the highest quartile of MR-proADM to
atients in quartiles 1 through 3 resulted in an HR for death
f 3.3 (95% CI: 2.0 to 5.4, p  0.001).
iscussion
his multinational trial, the largest of its kind to date,
emonstrated that mid-region prohormone markers have
ignificant diagnostic and prognostic utility in patients
resenting in the ED with acute dyspnea. Our findings
alidate and extend the observations made in previous pilot
tudies using MR-proANP for the diagnosis of heart failure
18) and MR-proADM for the assessment of prognosis
15–17,19).
MR-proANP is equivalent to BNP or NTproBNP in
he diagnosis of AHF in patients presenting with short-
NP, and MR-proADM foritalization, Revisit, or Anyial Presentation to ED, NT-proBNP, and MR-proADM for
eath, Rehospitalization, Revisit, or Any
Days After Initial Presentation to ED
AUC
MR-proADM BNP NT-proBNP
0.674 0.606 0.664
0.739 0.555 0.641
0.727 0.512 0.620
0.740 0.682 0.724
0.790 0.584 0.651
0.728 0.525 0.613
0.510 0.593 0.536
0.510 0.569 0.501
0.544 0.560 0.541
0.504 0.620 0.540
0.509 0.600 0.512
0.533 0.554 0.545
0.519 0.560 0.508
0.501 0.608 0.516
0.686 0.600 0.667
0.519 0.601 0.515
0.507 0.606 0.507
0.694 0.673 0.745
0.551 0.588 0.565
0.550 0.561 0.535
0.501 0.546 0.515
0.551 0.620 0.570
0.565 0.583 0.538
0.530 0.542 0.512
ullin; other abbreviations as in Tables 2 and 3.-proBehospfte Infor
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May 11, 2010:2062–76 Mid-Region Pro-Hormone Markers in Acute DyspnearoANP for making the diagnosis of AHF was based
n prior studies (17,18), and was specified a priori in
he study protocol as 120 pmol/l. The present find-
Figure 4 Comparison of Prognostic Biomarkers
Area under the receiver-operating characteristic curve (AUC) for BNP (blue lines), N
for prediction of (left) all-cause and (right) cardiovascular death (top), rehospitaliz
tions as in Figure 1.ngs suggest that a cut point of 130 pmol/l more slosely matches a BNP cut point of 100 pg/ml. The
alculated AUCs for MR-proANP, NTproBNP, and
NP were 0.90, 0.90, and 0.91, respectively. In the
NP (green lines), and mid-regional pro-adrenomedullin (MR-proADM) (red lines)
(middle), and revisit (bottom) within 90 days after initial presentation. Abbrevia-T-proB
ationubgroup of 655 patients whose values for BNP or
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Mid-Region Pro-Hormone Markers in Acute Dyspnea May 11, 2010:2062–76T-proBNP were not available to the clinicians at the
ime of diagnosis, the calculated AUCs for MR-proANP
nd BNP were 0.904 in both cases, but significantly lower
or NT proBNP. MR-proANP levels may provide addi-
ional diagnostic information for the diagnosis of AHF in
ddition to BNP or NT-proBNP levels in subgroups for
hich a correct diagnosis is considered difficult but
linically highly desirable (22–24).
In the prognostic portion of the study, we determined
hat MR-proADM was superior to BNP and NT-
roBNP for predicting 90-day mortality in patients with
yspnea due to AHF. This finding was especially true in
n exploratory analysis of the important first 30 days after
aseline evaluation, for which MR-proADM clearly out-
erformed BNP and NT-proBNP. Troponin, which was
ecently shown to carry prognostic value in patients with
eart failure (25), was also added to a multivariable model
ith the other 3 markers. In this model, MR-proADM
till remained an independent prognostic factor. In the
Figure 5 Comparison of Prognostic Biomarkers for Patients Wi
Area under the receiver-operating characteristic curve (AUC) for BNP (blue lines), N
(left) all-cause and (right) cardiovascular rehospitalization (top) and revisit (botto68 BACH patients with a confirmed diagnosis of AHF t65 deaths within 90 days), the prognostic accuracy of
R-proADM levels assessed in blood samples taken on
dmission to the ED was 73%. It was found to be lower
or BNP and NT-proBNP (62% and 64%, respectively).
his was also true when considering all 1,641 enrolled
atients, regardless of final diagnosis (data not shown).
None of the biomarkers was able to predict rehospital-
zation or revisit to the ED with a clinically relevant
erformance.
tudy limitations. Although we have identified patients at
igher risk, as this was a diagnostic study with no random-
zed intervention above standard care, we cannot comment
n the effects of intervention in patients identified as higher
isk. As BNP is already part of the standard diagnostic
orkup in many hospitals, it was therefore regarded as
nethical to withhold measurement of BNP at presentation
or the diagnosis by the treating physician. Procedurally, it
as also not possible to blind the gold standard physicians
rom biomarker levels taken at the site. Therefore, evalua-
BNP Measurement at Time of Evaluation (n  166)
NP (green lines), and MR-proADM (red lines) for prediction of
hin 90 days after initial presentation. Abbreviations as in Figures 1 and 4.thout
T-proB
m) wition of BNP for diagnosis of AHF could lead to positively
Single Predictor and Multivariable Cox Proportional Hazard Models for Survival Among Patients With Acute Heart Failure (n  568)Table 6 Single Predictor and Multivariable Cox Proportional Hazard Models for Survival Among Patients With Acute Heart Failure (n  568)
Predictor
Model 1 Model 2
Model 3
Unadjusted Adjusted for Age (yrs) and Sex
Adjusted for Age (yrs), Sex, BMI (kg/m2),
and Creatinine (>1.6 mg/dl)
HR 95% CI Chi-Square p Value n HR 95% CI Chi-Square p Value n HR 95% CI Chi-Square p Value n
Single predictor analysis (using 1 biomarker at a time)
Log MR-proADM, nmol/l 2.4 1.8–3.3 31 <0.0001 564 2.4 1.8–3.2 30.5 <0.0001 564 2.3 1.6–3.4 18.8 <0.0001 505
Log BNP, pg/ml 1.5 1.1–2.1 7.1 0.008 566 1.6 1.1–2.2 8.0 0.005 566 1.3 0.9–1.9 2.2 0.137 507
Log NT-proBNP, pg/ml 2.0 1.4–2.9 17.1 <0.0001 562 1.9 1.4–2.7 14.2 0.0002 562 1.5 1.0–2.3 4.2 0.041 504
Troponin, high/low 3.2 1.9–5.4 16.5 <0.0001 511 3.2 1.9–5.5 17.8 <0.0001 511 3.2 1.8–5.7 15.7 0.0001 468
Multivariable analysis 1: MR-proADM and BNP
Log MR-proADM, nmol/l 2.4 1.7–3.4 24.9 <0.0001 563 2.3 1.6–3.3 21.3 <0.0001 563 2.4 1.6–3.7 16.2 <0.0001 504
Log BNP, pg/ml 1.0 0.7–1.5 0.0 0.91 563 1.1 0.7–1.6 0.2 0.70 563 0.9 0.6–1.4 0.1 0.71 504
Multivariable analysis 2: MR-proADM, BNP, and
troponin
Log MR-proADM, nmol/l 2.0 1.4–2.9 13.6 0.0002 508 2.0 1.3–2.9 11.6 0.0006 508 2.1 1.4–3.4 10.6 0.0011 465
Log BNP, pg/ml 1.0 0.6–1.4 0.1 0.81 508 1.0 0.7–1.5 0.0 0.94 508 0.9 0.6–1.4 0.3 0.57 465
Troponin, high/low 2.6 1.5–4.5 11.0 0.0009 508 2.6 1.5–4.6 10.9 0.0009 508 2.9 1.6–5.2 11.9 0.0005 465
Multivariable analysis 3: MR-proADM and NT-proBNP
Log MR-proADM, nmol/l 2.2 1.5–3.1 16.0 <0.0001 559 2.1 1.5–3.1 15.0 <0.0001 559 2.5 1.6–4.0 14.4 <0.0001 501
Log NT-proBNP, pg/ml 1.3 0.8–1.9 1.1 0.30 559 1.2 0.8–1.8 0.9 0.35 559 0.9 0.6–1.5 0.1 0.83 501
Multivariable analysis 4: MR-proADM, NT-proBNP, and
troponin
Log MR-proADM, nmol/l 1.9 1.3–2.9 9.9 0.0016 503 2.0 1.3–3.0 9.7 0.0018 503 2.4 1.4–4.0 11.3 0.0008 461
Log NT-proBNP, pg/ml 1.1 0.7–1.6 0.1 0.77 503 1.0 0.7–1.6 0.0 0.96 503 0.8 0.5–1.4 0.5 0.46 461
Troponin, high/low 2.6 1.5–4.4 11.1 0.0009 503 2.6 1.5–4.6 11.3 0.0008 503 3.0 1.6–5.4 12.9 0.0003 461
For each biomarker, and therefore for all reported chi-square, degree of freedom  1. Bold values indicate statistical significance.
Abbreviations as in Tables 2 to 5.
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Mid-Region Pro-Hormone Markers in Acute Dyspnea May 11, 2010:2062–76iased results to an unknown extent. Therefore, we had to
ccept this bias in favor of BNP, and selected a noninferi-
rity design with a margin of 10%. Nonetheless, the
bserved difference in accuracy was 1%. When patients
ith known clinical laboratory values for BNP or NT-
roBNP were excluded, the AUCs for BNP and MR-
roANP were identical. In addition, the knowledge of BNP
ight have also influenced the classification of an outcome
vent as cardiovascular, which again biases prediction results
n favor of BNP. Again, when patients with known clinical
aboratory values for BNP were excluded, the observed
dvantages of BNP for predicting cardiovascular events
anished. However, this finding must be interpreted cau-
iously as this subset of patients is not representative of
he group as a whole. Finally, the number of deaths
mong patients with AHF was limited by the 90-day
ollow-up duration, so longer term prognosis cannot be
ddressed.
onclusions
linical implications. The value of natriuretic peptides in
he diagnostic and prognostic assessment of patients with
ongestive heart failure is reflected in their inclusion in
uidelines across the world (26–28) as well as by a recent
onsensus statements (29). Mid-regional prohormone
arkers are very stable in blood samples kept at room
emperature, and hence may offer some practical analytical
Figure 6 AUC for Survival to 90 Days
Area under the receiver-operating characteristic curve (AUC) for survival to 90
days for MR-proADM (red line), BNP (blue line), and NT-proBNP (green line) in
acute heart failure patients. Curves smoothed by a locally weighted polynomial
regression. Abbreviations as in Figures 1 and 4.dvantages (30). The tests for MR-proANP and MR- IroADM are now available in a fast-assessment format,
aking diagnostic and prognostic information available to
he acute care physician within 30 to 60 min. Thus,
R-proANP can now be considered the third valid natri-
retic peptide marker for heart failure patients. While it
eed not replace the other peptides for diagnosis of heart
ailure, use of MR-proANP levels are acceptable alterna-
ives, depending on the laboratory platform available, pric-
ng, and so forth, and may add to the other natriuretic
eptide levels in ambivalent diagnostic cases.
Better prognostic markers help patients in many ways, as
hey identify those patients who should “move to the front
f the line” with respect to immediate therapeutic interven-
ions. In the emergency setting, untreated AHF worsens
apidly and can lead to respiratory compromise, intubation
ith mechanical ventilation, and even death. Thus, inter-
entions based on high MR-proADM levels might include
pecialist consultation by a cardiologist, intensive care unit
dmission, noninvasive ventilation, and so forth. Addition-
lly, the astute clinician will more closely follow up patients
ith poor prognostic markers after discharge to prevent
elapse and readmission. MR-proADM may also help to
dentify patients who are in need of longer courses of
npatient therapy to relieve congestion. MR-proADM lev-
ls may also serve as a surrogate marker in therapeutic heart
ailure trials, although both of these suggestions require
alidation.
uthor Disclosures
r. Maisel has received research support from Roche,
iosite, and Bayer, and is a consultant to Biosite. Dr. Mueller
as received research grants from the Swiss National Sci-
nce Foundation, the Swiss Heart Foundation, the Novartis
oundation, the Krokus Foundation, Abbott, Biosite,
RAHMS, Roche, and the University of Basel. Dr. Pea-
ock is on the Scientific Advisory Board of Abbott,
eckman-Coulter, Biosite, Inverness, Ortho Clinical Diag-
ostics, and Response Biomedical, and has received research
rants from Abbott, Biosite, and Inverness. Dr. Ponikowski
as received honoraria for serving as a consultant for Vifor
nd Athera, and as a speaker for Merck-Serono, Pfizer, and
anofi-Aventis. Dr. Richards is on the Scientific Advisory
oard of Inverness Medical, and has received travel support,
onoraria, and research grants from Roche Diagnostics and
nverness Medical (Biosite). Dr. Filippatos has received
esearch support from Biosite, BRAHMS, and Roche. Dr.
i Somma is a consultant to Biosite. Dr. Ng is a consultant
or Inverness Medical Innovations and BRAHMS AG.
r. Daniels has received research support from Biosite
nc. and Roche Diagnostics. Dr. Neath is a consultant to
RAHMS USA. Dr. Christensen is a consultant for Sie-
ens, BG-Medicine, Critical Care Diagnostics, Inverness
edical, and Abbott Diagnostics, and has received research
upport from Siemens, BG-Medicine, BRAHMS, Roche,
nverness Medical, and Nanosphere. Dr. McCord has
r
O
i
p
a
h
o
t
D
A
h
2075JACC Vol. 55, No. 19, 2010 Maisel et al.
May 11, 2010:2062–76 Mid-Region Pro-Hormone Markers in Acute Dyspneaeceived research funding from BRAHMS Diagnostics.
liver Hartmann is an employee of BRAHMS AG, which
s a company developing and marketing in vitro diagnostic
roducts, including the MR-proANP and MR-proADM
ssays used in this study. Dr. von Haehling has received
Figure 7 Kaplan-Meier Survival Curves
Kaplan-Meier survival curves by quartiles of MR-proADM, NT-proBNP, and BNP for 568
(B) Results for quartiles of NT-proBNP. (C) Results for quartiles of BNP. CI  confionoraria from BRAHMS. Dr. Bergmann is an employee tf BRAHMS AG, holds patent applications related to
his technology, and is a shareholder of BRAHMS AG.
r. Morgenthaler is an employee of BRAHMS AG. Dr.
nker has received research support from BRAHMS,
onoraria from Abbott and Biosite, and is a consultant
ts with acute heart failure. (A) Results for quartiles of MR-proADM.
interval; HR  heart failure; other abbreviations as in Figures 1 and 4.patien
denceo BRAHMS.
A
T
a
w
R
D
V
u
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
2076 Maisel et al. JACC Vol. 55, No. 19, 2010
Mid-Region Pro-Hormone Markers in Acute Dyspnea May 11, 2010:2062–76cknowledgments
he BACH Investigators would like to thank Scott Mader
nd CLINDEVOR TriMed for clinical trial monitoring as
ell as for committee and investigator meeting organization.
eprint requests and correspondence: Dr. Alan Maisel, VA San
iego Healthcare System Cardiology 9111-A, 3350 La Jolla
illage Drive, San Diego, California 92161. E-mail: amaisel@
csd.edu.
EFERENCES
1. Wuerz RC, Meador SA. Effects of prehospital medications on
mortality and length of stay in congestive heart failure. Ann Emerg
Med 1992;21:669–74.
2. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic
peptide in the evaluation and management of acute dyspnea. N Engl
J Med 2004;350:647–54.
3. Maisel AS, Peacock WF, McMullin N, et al. Timing of immunore-
active B-type natriuretic peptide levels and treatment delay in acute
decompensated heart failure: an ADHERE (Acute Decompensated
Heart Failure National Registry) analysis. J Am Coll Cardiol 2008;
52:534–40.
4. Farmakis D, Filippatos G, Tubaro M, et al. Natriuretic peptides in
acute coronary syndromes: prognostic value and clinical implications.
Congest Heart Fail 2008;14 Suppl 1:25–9.
5. Jougasaki M, Burnett JC Jr. Adrenomedullin: potential in physiology
and pathophysiology. Life Sci 2000;66:855–72.
6. Jougasaki M, Rodeheffer RJ, Redfield MM, et al. Cardiac secretion of
adrenomedullin in human heart failure. J Clin Invest 1996;97:2370–6.
7. Jougasaki M, Wei CM, McKinley LJ, Burnett JC. Elevation of
circulating and ventricular adrenomedullin in human congestive heart
failure. Circulation 1995;92:286–9.
8. Nishikimi T, Saito Y, Kitamura KI, et al. Increased plasma levels of
adrenomedullin in patients with heart failure. J Am Coll Cardiol
1995;26:1424–31.
9. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an
adrenomedullin precursor fragment in plasma of sepsis patients.
Peptides 2004;25:1369–72.
0. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of
midregional proadrenomedullin in plasma with an immunolumino-
metric assay. Clin Chem 2005;51:1823–9.
1. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunolumi-
nometric assay for the midregion of pro-atrial natriuretic Peptide in
human plasma. Clin Chem 2004;50:234–6.
2. Caruhel P, Mazier C, Kunde J, Morgenthaler NG, Darbouret B.
Homogeneous time-resolved fluoroimmunoassay for the measurement
of midregional proadrenomedullin in plasma on the fully automated
system B.R.A.H.M.S KRYPTOR. Clin Biochem 2009;42:725–8.
3. Leroy O, Santre C, Beuscart C, et al. A five-year study of severe
community-acquired pneumonia with emphasis on prognosis in patients
admitted to an intensive care unit. Intens Care Med 1995;21:24–31.
4. Fine MJ, Smith DN, Singer DE. Hospitalization decision in patients
with community-acquired pneumonia: a prospective cohort study.
Am J Med 1990;89:713–21.
5. Khan SQ, Dhillon O, Kelly D, et al. Plasma N-terminal B-type
natriuretic peptide as an indicator of long-term survival after acute Kmyocardial infarction: comparison with plasma midregional pro-atrial
natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction
Peptide) study. J Am Coll Cardiol 2008;51:1857–64.
6. Khan SQ, O’Brien RJ, Struck J, et al. Prognostic value of midregional
pro-adrenomedullin in patients with acute myocardial infarction: the
LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am
Coll Cardiol 2007;49:1525–32.
7. von Haehling S, Jankowska EA, Morgenthaler NG, et al. Comparison
of midregional pro-atrial natriuretic peptide with N-terminal pro-B-
type natriuretic peptide in predicting survival in patients with chronic
heart failure. J Am Coll Cardiol 2007;50:1973–80.
8. Gegenhuber A, Struck J, Poelz W, et al. Midregional pro-A-type
natriuretic peptide measurements for diagnosis of acute destabilized
heart failure in short-of-breath patients: comparison with B-type
natriuretic peptide (BNP) and amino-terminal proBNP. Clin Chem
2006;52:827–31.
9. Gegenhuber A, Struck J, Dieplinger B, et al. Comparative evaluation
of B-type natriuretic peptide, mid-regional pro-A-type natriuretic
peptide, mid-regional pro-adrenomedullin, and copeptin to predict
1-year mortality in patients with acute destabilized heart failure. J Card
Fail 2007;13:42–9.
0. DeLong ER, DeLong DM, Coarke-Pearson DL. Comparing the
areas under two or more correlated receiver operating characteristic
curves: a nonparametric approach. Biometrics 1988;44:837–45.
1. Pencina MJ, D’Agostino RB Sr., D’Agostino RB Jr., Vasan RS.
Evaluating the added predictive ability of a new marker: from area
under the ROC curve to reclassification and beyond. Stat Med
2008;27:157–72.
2. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic
peptide and clinical judgment in emergency diagnosis of heart failure:
analysis from Breathing Not Properly (BNP) multinational study.
Circulation 2002;106:416.
3. McCord J, Mundy BJ, Hudson MP, et al. Relationship between
obesity and B-type natriuretic peptide levels. Arch Intern Med
2004;164:2247–52.
4. Möckel M, Müller R, Vollert JO, et al. Role of N-terminal pro-B-type
natriuretic peptide in risk stratification in patients presenting in the
emergency room. Clin Chem 2005;51:1624–31.
5. Peacock WF, De Marco T, Fonarow GC, et al. Cardiac troponin and
outcome in acute heart failure. N Engl J Med 2008;358:2117–26.
6. European Society of Cardiology; Heart Failure Association of the
ESC (HFA); European Society of Intensive Care Medicine (ESICM),
Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for
the diagnosis and treatment of acute and chronic heart failure 2008.
Eur J Heart Fail 2008;10:933–89.
7. Nieminen MS, Böhm M, Cowie MR, et al. Executive summary of the
guidelines on the diagnosis and treatment of acute heart failure: the
Task Force on Acute Heart Failure on the European Society of
Cardiology. Eur Heart J 2005;26:384–416.
8. ACC/AHA collaborate on guidelines for the evaluation and manage-
ment of heart failure. Am Fam Physician 1996;53:2196–8.
9. Maisel A, Mueller C, Adams K Jr., et al. State of the art: using
natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;
10:824–39.
0. Ala-Kopsala M, Magga J, Peuhkurinen K, et al. Molecular heteroge-
neity has a major impact on the measurement of circulating
N-terminal fragments of A- and B-type natriuretic peptides. Clin
Chem 2004;50:1576–88.ey Words: pro-hormone y markers y acute dyspnea y BACH.
